Jennifer Herron

Jennifer Herron is the Senior Vice President and Chief Commercial Officer at ADC Therapeutics, a biotechnology company focused on developing antibody-drug conjugates for cancer treatment. She assumed this role on November 4, 2019, where she is responsible for leading all global commercial activities and is a key member of the senior management team.14

Professional Background

Herron has over 27 years of experience in the biotechnology and pharmaceutical sectors. Before joining ADC Therapeutics, she served as Executive Vice President and Chief Commercial Officer at Immunogen, where she was instrumental in the pre-commercialization planning of mirvetuximab soravtansine, an innovative antibody-drug conjugate targeting folate receptor alpha.1 Additionally, she held significant positions at MorphoSys US and Ariad Pharmaceuticals, where she led global commercialization efforts for various oncology products.13

Education

Jennifer Herron holds an MBA from Georgetown University and a B.A. in Biology and Economics from Lehigh University, which complement her extensive experience in commercial leadership within the pharmaceutical industry.1

Recognition

In 2022, Herron was recognized by PM360 Magazine as one of the PM360 ELITE for her expertise in product launches within the pharmaceutical sector.23

Overall, her leadership at ADC Therapeutics is marked by a commitment to improving outcomes for cancer patients through innovative therapies and strategic commercial initiatives.